首页> 外国专利> IDENTIFICATION OF L. DONOVANI SPECIFIC 70 KDA, 37 KDA AND 12.6 KDA PROMASTIGOTE ANTIGENS FOR THE DIAGNOSIS OF INDIAN VISCERAL LEISHMANIASIS'.

IDENTIFICATION OF L. DONOVANI SPECIFIC 70 KDA, 37 KDA AND 12.6 KDA PROMASTIGOTE ANTIGENS FOR THE DIAGNOSIS OF INDIAN VISCERAL LEISHMANIASIS'.

机译:鉴别用于诊断印度内脏利什曼病的L. DONOVANI特异抗原70 KDA,37 KDA和12.6 KDA促成药。”

摘要

Diagnosis of Visceral Leishmaniasis (VL) is based on microscopic demonstration of amastigote in splenic/bone marrow smears, but these are painful and risky process. Serodiagnosis using recombinant k39 antigen has been a significant advance in management of VL, however, being positive in 20-32% healthy individuals is an important drawback. In this study we have identified three novel antigens of Leishmania donovani comprising of 70 kDa, 37 kDa and 12 kDa protein through western blotting. We analyzed the antibody response against crude soluble antigen (CSA) of L. donovani in VL patients (before and after treatment), in endemic healthy (EHC) and non endemic healthy controls (NEHC). Our results suggest that the antibody response against this antigen is predominantly found in serum of all VL patients even after the successful treatment but is not present in the endemic and non endemic healthy controls. To validate immunoblotting results, we partially purified this antigen by gel elution and performed indirect enzyme linked immunosorbent assay (ELISA) on VL patients, NEHC, EHC and different disease controls. The sensitivity and specificity of all three proteins in case of viceral leishmaniasis, endemic healthy, non endemic healthy and different disease group was described above respectively. We further characterized these proteins through 2D gel electrophoresis and MALDI-TOF followed by trypsin digestion. Results suggest that the BHU P-l protein is a heat shock protein of 70 kDa and 653 amino acids, second is BHU P-2 protein of 37 kDa which is new one in case leishmania donovani and third one is of 12 kDa and 113 amino acids is also a new protein in case of leishmania donovani. Because of their high sensitivity and specificity, these antigens have great potential for further development as tool for diagnosis of VL.
机译:内脏利什曼病(VL)的诊断基于脾脏/骨髓涂片中的鞭毛体的显微镜显示,但这些过程痛苦且危险。使用重组k39抗原的血清诊断在VL的管理方面已取得了重大进展,但是,在20-32%的健康个体中呈阳性是一个重要的缺点。在这项研究中,我们已经通过免疫印迹鉴定了三种新的利什曼原虫新抗原,包括70 kDa,37 kDa和12 kDa蛋白。我们分析了VL患者(治疗前和治疗后),地方健康人群(EHC)和非地方健康人群(NEHC)针对多诺氏乳杆菌的粗可溶性抗原(CSA)的抗体反应。我们的结果表明,即使在成功治疗后,所有VL患者的血清中也普遍发现了针对该抗原的抗体反应,但在地方性和非地方性健康对照中均不存在。为了验证免疫印迹结果,我们通过凝胶洗脱部分纯化了该抗原,并对VL患者,NEHC,EHC和不同疾病对照进行了间接酶联免疫吸附测定(ELISA)。上面分别描述了三种蛋白在副性利什曼病,地方性健康,非地方性健康和不同疾病组中的敏感性和特异性。我们通过2D凝胶电泳和MALDI-TOF,然后进行胰蛋白酶消化,进一步表征了这些蛋白质。结果表明BHU Pl蛋白是70 kDa和653个氨基酸的热激蛋白,第二个是37 kDa的BHU P-2蛋白,在多形性利什曼原虫的情况下是新的,而第三个是12 kDa和113个氨基酸。也是在利什曼原虫中的一种新蛋白质。由于它们的高灵敏度和特异性,这些抗原作为VL诊断工具具有巨大的潜力,可以进一步开发。

著录项

  • 公开/公告号IN2010DE02939A

    专利类型

  • 公开/公告日2013-01-11

    原文格式PDF

  • 申请/专利权人

    申请/专利号IN2939/DEL/2010

  • 发明设计人 DR SHYAM SUNDAR;DINESH KUMAR;SUBODH KUMAR;

    申请日2010-12-09

  • 分类号

  • 国家 IN

  • 入库时间 2022-08-21 16:41:30

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号